Phase 2, Open-Label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma

Trial Profile

Phase 2, Open-Label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Trebananib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 25 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2015 to 1 Jul 2015.
    • 22 Apr 2014 Planned end date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top